The dilutive offering at a ~20% discount signals near-term cash constraints. Monitor the stock for continued pressure as the market absorbs the new shares. The path to value creation depends on interim data from the Phase 2 CRDF-004 trial in RAS-mutated mCRC and the pending stockholder vote to increase authorized shares for warrant exercise. Until catalysts emerge, the overhang from the dilutive structure and potential future equity needs may limit upside.
Price Chart
Executive Summary
Cardiff Oncology is raising approximately $9.1 million in net proceeds through a registered direct offering of 9,293,078 shares of common stock and accompanying warrants priced at $1.05 per unit ($1.455 for insiders), representing a ~20% discount to the prior day's close. The offering causes immediate dilution of $0.52 per share to new investors and signals a cash need that may cap upside until clinical data readouts from the Phase 2 CRDF-004 trial emerge.
Key Facts
- 9,293,078 shares of common stock and warrants offered at $1.05 per share ($1.455 for insiders), representing a ~20% discount to the $1.31 closing price on July 14, 2026
- Expected net proceeds of approximately $9.1 million for general corporate and working capital purposes
- Common stock outstanding post-offering: 77,795,248 shares (excluding warrants), a 13.6% increase from 68,502,170 shares
- Common warrants exercisable at $1.31 per share ($1.33 for insiders), subject to stockholder approval of an authorized share increase
- Immediate dilution of $0.52 per share to new investors; as-adjusted net tangible book value rises to $0.56 per share from $0.51
- H.C. Wainwright & Co. acting as exclusive placement agent with 7.0% cash fee and 5.0% warrant coverage
- 60-day lock-up on the company and directors/officers; 90-day prohibition on variable rate transactions
- Auditor's report includes going concern explanatory paragraph
Financial Impact
Gross proceeds of $10,050,000; net proceeds of ~$9.1 million. Dilution of $0.52 per share (~48% of offering price). Outstanding share count increases by 13.6%.
Risk Factors
- Immediate dilution of $0.52 per share reduces ownership for existing holders
- Offering at a discount to market price signals financing urgency
- Going concern explanatory paragraph in audited financials highlights cash burn risk
- Future warrant exercise requires stockholder approval for an authorized share increase, creating execution uncertainty
- Nasdaq listing compliance risk if share price falls below $1.00 threshold
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-305465 |
| Document: 0001193125-26-305465-index-headers.html | 0001193125-26-305465 |
| Document: 0001193125-26-305465-index.html | 0001193125-26-305465 |
| Document: 0001193125-26-305465.txt | 0001193125-26-305465 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $1.33 $1.17 | ▲ +12.03% | ▲ +10.84% | $0.8043 (+39.53%) |
Sep 14, 2026 6w ago | 8-K | $1.31 $1.37 | ▲ +4.58% | ▲ +4.47% | $0.8043 (−38.60%) |
Aug 11, 2026 10w ago | Press Release | $0.9900 $0.8979 | ▲ +9.30% | ▲ +8.86% | $0.8043 (+18.76%) |
Jul 16, 2026 14w ago | Insider Cluster | $0.8800 $0.8381 | ▼ −4.76% | ▼ −4.07% | $0.8043 (−8.60%) |
Jul 16, 2026 14w ago | 8-K | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8043 (+8.03%) |
Jul 16, 2026 14w ago | 424B5 | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8043 (+8.03%) |
Jun 22, 2026 18w ago | Insider Cluster | $1.30 $1.25 | ▼ −3.85% | ▼ −1.78% | $0.8043 (−38.13%) |
Jun 11, 2026 19w ago | Institutional Cluster | $1.59 $1.18 | ▲ +25.79% | ▲ +26.22% | $0.8043 (+49.42%) |
Jun 3, 2026 20w ago | 8-K | $1.40 $1.48 | ▲ +5.71% | ▲ +9.53% | $0.8043 (−42.55%) |
Jun 2, 2026 20w ago | Press Release | $1.51 $1.53 | ▲ +1.32% | ▲ +4.29% | $0.8043 (−46.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers